700454Market study for diagnostic biosensorsClosedGRD Proof of MarketInnovate UKSarissa Biomedical develops & sells microelectronic (enzymatic) biosensors. Its devices are highly sensitive, selective & able to measure analytes in biological tissues & fluids such as unprocessed whole blood making them ideal for point of care diagnostics (PoC). Sarissa has identified a number of diseases where biomarkers have been proposed but the technology to accurately measure them outside a pathlab does not exist. Sarissa’s solution potentially provides a very low cost bedside/ PoC solution as an alternative to existing slow, capital intensive and high-skilled pathlab operation. The Company is currently working with a number of hospitals & Universities on clinical trials to validate biomarkers and using Sarissa’s technology to directly measure these biomarkers in whole blood. Target diseases include stroke, sepsis and foetal hypoxia. Whilst highly effective therapies exist for these diseases, the critical factor for a positive outcome is early intervention. Unfortunately current diagnostics for these conditions are slow, expensive and requiring specialist clinicians. As a result patients regularly have poor outcomes. Sarissa’s technology has the potential to transform the treatment of these conditions. The successful adoption of any new medical technology requires a clear understanding of the clinical pathway, regulatory conditions, health economics and budgetary factors of the various healthcare provider. This Proof of Market study is aimed at researching these issues to provide an understanding of the market opportunity and, in particular, where within the existing clinical pathway adoption is most likely to occur and the regulatory issues that will need to be addressed. The study will be critical in developing a business and investment plan to drive future growth of the company.